Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013395 (dyspepsia)
 4,879 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

"Indigestion" caused by organic and functional alterations in the biliary ways was examined. The difficulty of accurately identifying this form of dyspepsia, whose frequency explains the interest it arouses, is emphasised. Dyspepsia attributable to dyskinesia of the biliary ways and post-cholecystectomy syndrome is specifically analysed. After a review of the results obtained by the medical and surgical treatment of biliary dyspepsia, a more accurate nosologic and pathogenetic classification of the disease is recommended, together with a more detailed definition of the action mechanism of the biliary acids.
Minerva Med 1984 Sep 08
PMID:[Bile-dependent gastrointestinal dyspepsia]. 648 49

Patients with a clinical diagnosis of 'gastritis' or non-ulcer dyspepsia were studied as to the extent and pattern of drugs prescribed from October 1978 through September 1981. This was permitted by the Diagnosis and Therapy Survey, an ongoing nationwide sample study, covering all outpatient care in Sweden. In 98% of the consultations a drug was considered to be indicated. Antacids were prescribed in 76%, an anticholinergic drug in 40%, and a histamine-H2-receptor antagonist (cimetidine) in 3%. The latter figure seemed to increase during the 3-year study period, concomitant with a decrease in the prescription rate of anticholinergic drugs. Gastritis was the major indication not only for antacids and anticholinergic drugs but also for cimetidine, accounting for 35% of all cimetidine prescriptions. Total sales of these drugs in 1981 amounted to about SKR 150 million. Antacids comprised 57%, anticholinergic/spasmolytics 22%, and cimetidine 21% of this amount. The extensive drug use is remarkable considering the lack of convincing data from randomized controlled clinical trials supporting a therapeutic effect of any drug regimen in gastritis. More such trials in well-defined patient groups are therefore greatly needed.
Scand J Gastroenterol 1984 Sep
PMID:The clinical diagnosis of gastritis. II. Aspects of current therapy and drug consumption. 651 15

Painful epigastric syndrome where gastroenteric or extra-digestive lesions are not revealed by common investigatory techniques (x-rays, endoscopy) are often diagnosed as primary or functional dyspepsia. This review is important because about half of the sufferers complain of functional gastroenteric disorders. The term "Dyspepsia" is reviewed on the basis of old and more recent literature together with long personal experience. The overall results confirm the existence of Dyspepsia as a separate complaint in its own right. The importance of Dyspepsia should be fully understood since a correct diagnosis avoids the need of further checks and choice of pharmaceutical treatment is made easier. Support psychotherapy and diet revision are also facilitated.
Minerva Med 1983 Sep 22
PMID:[A difficult diagnosis: dyspepsia]. 662 4

One hundred and ninety-nine male London office workers with dyspeptic symptoms elicited by a self-administered questionnaire were randomly allocated to intervention and control groups to assess the potential benefits of screening. The members of the intervention group were interviewed and examined, and those men who were considered to have a possible or probable peptic ulcer received a barium meal examination (53%). At the clinical interview the intervention group were advised against both smoking and drinking alcohol. Eighteen months later both groups were recalled for interview and examination and their sickness absence in the intervening period was assessed. The intervention group did not alter their cigarette consumption but did reduce their alcohol intake by an average of 10%. The control group increased their alcohol intake by 20%. Both groups tended to improve symptomatically, and there were no differences in symptoms between the groups at the end of the study. Sickness absence was not affected by the intervention. It is concluded that screening for ulcer-type dyspepsia is not justifiable in male London office workers.
J Epidemiol Community Health 1982 Sep
PMID:A randomised controlled trial of the effects of screening for ulcer-type dyspepsia. 675 44

Seventy two patients admitted to a medical department with dyspepsia but without a previous diagnosis of peptic ulcer disease or chronic pancreatitis were studied consecutively. A pancreatic function test (Lundh meal test) and an upper endoscopy was made in all patients. There was no difference in age, sex ratio, occurrence of upper abdominal pain or chronic alcoholism between the groups of patients with reduced pancreatic function (20) and the group with normal function (52). Seven duodenal ulcers were found, two in patients with normal pancreatic function (2/52 = 3.8%; 95% conf lim: 0.5-13.2) and five in patients with reduced pancreatic function (5/20 = 25%; 95% conf lim: 8.7-49.1). This difference was statistically significant (p less than 0.01). Duodenitis occurred with equal frequency in the two groups.
Gut 1983 Sep
PMID:Association between duodenal bulb ulceration and reduced exocrine pancreatic function. 688 16

Fenbufen (3(4-biphenyl-carbonyl) propionic acid) (Cinopal; Lederle) was administered as a single daily dose of 1000 mg for 4 weeks to 20 patients with rheumatoid arthritis. At 2 weeks, and again at the end of the trial, patients were assessed for duration of morning stiffness, number of painful and/or swollen joints, grip strength, walking time, and subjective response to treatment. Four patients failed to complete the trial, 2 because of inability to control symptoms and 2 because of severe rash attributed to the drug. The remaining 16 patients showed some improvement in most of the recorded parameters, with statistically significant reduction of morning stiffness and walking time. Apart from a maculopapular rash, which occurred in 4 patients and cleared up on stopping the fenbufen, side-effects were minimal. No patient complained of dyspepsia or epigastric pain.
S Afr Med J 1981 Sep 05
PMID:Fenbufen as a single daily dose in the treatment of rheumatoid arthritis. 702 59

Analysis of 7,966 hospital admissions and other available data suggest that disease associated with autoimmunity are rare in Ethiopia. Sera from 107 patients with dyspepsia and 80 healthy Ethiopians were studied for autoantibodies. Using the immunofluorescence technique and anti-Fab-FITC conjugate, a search for organ-specific autoantibodies against thyroid (microsomal and thyroglobulin) cells as well as for non-organ-specific autoantibodies against nuclear material, smooth muscle, mitochondria, cardiolipin, glomerular basement membrane and connective tissue (reticulin antibodies) revealed that they were uncommon. Thus, both clinical and serological studies confirm that previously held views concerning the rarity of autoimmune diseases in many parts of Africa are also true in Ethiopia. It is suggested that the few Ethiopians who develop autoimmune diseases may have an overwhelming hereditary predisposition which is unable to overcome inhibitory factors in the environment.
Trop Geogr Med 1980 Sep
PMID:Prevalence of autoimmune diseases and autoantibodies in Ethiopia. 719 28

A case of mixed connective tissue disease is described. It began as chronic juvenile arthritis and progressed to acquire the typical features of SLE, PSS and PM. Dyspepsia and the patient's poor general condition, by focussing attention on the digestion and absorption functions, revealed the presence of the gastrointestinal alterations that often accompany SSP.
Minerva Med 1981 Sep 22
PMID:[Gastrointestinal changes in mixed connective tissue disease. Apropos of a clinical case]. 727 57

To evaluate the frequency and type of gastroduodenal mucosal inflammatory changes in patients with symptomatic acid peptic disease and nonulcer dyspepsia, 100 patients with gastrointestinal symptoms indicative of acid peptic disease or dyspepsia and 10 control subjects were clinically evaluated and underwent radiographic, endoscopic, and biopsy studies of the stomach and duodenum. Clinical evaluation revealed that of the 100 patients, 61% had classic and 39% had atypical manifestations of acid peptic (ulcer) disease. Endoscopic and histologic evaluation revealed that 25 patients had peptic ulcer craters, 86-90% of whom had associated gastroduodenitis. Thirty-nine patients had acute and 20 patients had chronic gastroduodenitis without ulcer crater. Twelve symptomatic patients had no histologic changes in the gastroduodenal mucosa. Two of the ten control subjects had mild gastritis. In the 61% of the patients with classic manifestations of peptic ulcer disease, we could not clinically distinguish the 24 patients with craters, (40% of the classic group) from the 25 patients with acute gastroduodenitis without craters (41% of the classic group). As a result of this study of our group of patients, we believe that gastroduodenitis can be symptomatic and may present with the same manifestations as peptic ulcer crater. Further study will be required to determine whether gastroduodenitis is an independent entity or part of the spectrum of acid peptic (ulcer) disease.
Dig Dis Sci 1980 Sep
PMID:Gastroduodenitis. A broader concept of peptic ulcer disease. 741 90

The majority of patients with dyspepsia are managed in general practice. However, most of the literature on Helicobacter pylori and its association with gastrointestinal disease has originated from secondary care. This review summarizes the role of H pylori in dyspepsia from the perspective of primary care and suggests a new strategy for the management of dyspeptic patients in this setting. Recent meta-analyses and consensus statements have supported the use of eradication therapy as first-line treatment of peptic ulceration. Studies from primary care have supported the use of eradication therapy in patients who have H pylori related peptic ulcer disease and require long-term H2-antagonist medication, on both clinical benefit and cost-effectiveness grounds. Of the many regimens proposed for the eradication of H pylori, the best evidence supports a triple combination of bismuth, metronidazole and tetracycline. Regimens using proton pump inhibitors may be more acceptable to patients but lack good evidence from trials. Use of a positive serum enzyme-linked immunoabsorbent assay for H pylori antibodies as a criterion for endoscopic investigation has been shown to result in a 23% reduction in endoscopic workload. Further research should answer questions of importance to general practitioners, such as the role of eradication therapy in patients with nonulcer dyspepsia and the effectiveness of eradication of H pylori in the prevention of gastric cancer.
Br J Gen Pract 1995 Sep
PMID:Role of Helicobacter pylori in gastrointestinal disease: implications for primary care of a revolution in management of dyspepsia. 874 55


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>